TERNS PHARMACEUTICALS INC's ticker is TERN and the CUSIP is 880881107. A total of 46 filers reported holding TERNS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,838,365 | -59.2% | 167,480 | -67.5% | 0.22% | -69.3% |
| Q2 2023 | $4,510,451 | -47.2% | 515,480 | -28.5% | 0.72% | -62.9% |
| Q1 2023 | $8,540,677 | +13.8% | 721,341 | -2.2% | 1.94% | +7.0% |
| Q4 2022 | $7,505,908 | +40.9% | 737,319 | -18.4% | 1.81% | +70.7% |
| Q3 2022 | $5,326,000 | +206.8% | 904,119 | +29.2% | 1.06% | +234.7% |
| Q2 2022 | $1,736,000 | – | 700,000 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,099,309 | $13,015,819 | 9.59% |
| VR Adviser, LLC | 3,619,522 | $42,855,140 | 8.37% |
| Vivo Capital, LLC | 6,657,992 | $78,830,625 | 5.47% |
| Fairmount Funds Management LLC | 2,040,000 | $24,153,600 | 4.15% |
| Decheng Capital Management III (Cayman), LLC | 714,285 | $8,457,134 | 3.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 667,922 | $7,908,196 | 3.26% |
| Ikarian Capital, LLC | 721,341 | $8,540,677 | 1.94% |
| Orbimed Advisors | 7,619,135 | $90,210,558 | 1.77% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,448,275 | $40,827,576 | 1.72% |
| CROSSPOINT FINANCIAL, LLC | 12,054 | $142,719 | 1.54% |